Hypoparathyroidism: Integrating New Guidelines and Treatment Approaches

April 2, 2017 to April 2, 2018

Hypoparathyroidism is a rare endocrine disorder, affecting 37 out of 100,000 people in the US, with physical and cognitive manifestations that profoundly affect a patient’s quality of life. Importantly, there are no formal guidelines for the management of these complicated patients. Current management of hypoparathyroidism is based on clinical judgment and experience, attempts to address mineral abnormalities, and involves the use of high doses of oral calcium and calcitriol (active vitamin D) to facilitate intestinal calcium absorption. PTH replacement therapy may offer a new option in the management of these complex patients.

Hypoparathyroidism: Integrating New Guidelines and Treatment Approaches will provide clinicians who care for patients with thyroid diseases with the latest information on the management of hypoparathyroidism through expert guidance and evidence-based recommendations. The activity will allow clinicians to better recognize the condition, determine the place of emerging agents, and safely and effectively manage such complex patients.

Target Audience

This activity is intended for clinicians and researchers, including endocrinologists, internists, surgeons, basic scientists, and other health care professionals with a shared special interest in the latest advances in hormone research and clinical endocrinology.

Learning Objectives

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice. 

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Apply new insights on the epidemiology and symptom burden of hypoparathyroidism to the management of at-risk patients and for early recognition of hypoparathyroidism
  • Describe strategies for control of hypoparathyroidism and for the prevention and management of potential adverse effects of long-term calcium and vitamin D therapy
  • Evaluate the role of PTH replacement therapy in the management of hypoparathyroidism based on recent clinical trial findings and expert guidance

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
04/02/2017
Course expires: 
04/02/2018
Event starts: 
04/02/2017 - 6:30pm
Event ends: 
04/02/2018 - 9:30pm
Rating: 
5

John P. Bilezikian, MD
Professor of Pharmacology
Professor of Medicine
College of Physicians and Surgeons, Columbia University
New York, NY

Bart L. Clarke, MD
Professor of Medicine
Mayo Clinic College of Medicine
Rochester, MN

Michael Mannstadt, MD
Chief, Endocrine Unit
Massachusetts General Hospital
Boston, MA

Dolores Shoback, MD
Professor of Medicine
University of California
San Francisco, CA

DISCLOSURE POLICY 

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

Program Faculty
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
John P. Bilezikian, MD: Consultant: Amgen, Merck, NPS Pharmaceuticals, Radius Health; Principal Investigator: Amgen, NPS Pharmaceuticals
Bart L. Clarke, MD:

Michael Mannstadt, MD: Advisory Board Member: NPS Pharmaceuticals
Dolores Shoback, MD: Consultant: NPS Pharmaceuticals

Non-faculty Content Contributors
The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships:
Natalie E. Cusano, MD: Consultant:

The following SPC member who reviewed content for this activity reported no relevant financial relationship: 

The following SPC members reported relevant  financial relationships that they or their spouse/partner have with commercial interests:
Sarah Berga, MD: Advisory Board Member: Agile Therapeutics, Noven Pharmaceuticals, Watson Pharmaceuticals, Teva Pharmaceuticals, Shionogi; Consultant: AHC Media LLC, Shionogi
Paresh Dandona, MD, PhD, FRCP: Consultant/Speaker: AstraZeneca, Bristol-Myers Squibb, Janssen, Merck, Novo Nordisk
Irl B. Hirsch, MD: Consultant: Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support: Halozyme Therapeutics, Sanofi
Anton Luger, MD: Advisory Board/Investigator/Speaker: Novo Nordisk; Advisory Board/Speaker: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck Sharp & Dome, Novartis, Pfizer, Reckitt Benckiser, Takeda; Investigator: Roche
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E. Umpierrez, MD, CDE: Advisory Board/Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Grant Support, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron
Andrea L. Utz, MD, PhD: Investigator, Corcept Therapeutics, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and Rockpointe staff associated with the development of content for this reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
04/02/2017
Course expires: 
04/02/2018